A practical reference on reverse-phase HPLC: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-12-04 and is reviewed periodically as new material appears.
Once dissolved, the peptide is far less stable than the dry powder. Aqueous solutions are subject to hydrolysis, oxidation at susceptible residues and gradual loss of material through adsorption onto glass and plastic surfaces. Terminal glutamine can cyclise under some conditions, producing a related species that complicates purity assessment. Dilute solutions tend to lose a larger fraction of material to surfaces than concentrated ones. Buffers, pH and ionic strength all influence the rate of change, so stability figures are only meaningful when those parameters are stated alongside the storage interval.
Detection in biological samples relies on mass spectrometry, typically liquid chromatography coupled to tandem mass spectrometry after peptide extraction and enrichment. Intact peptides can also be confirmed by high-resolution mass measurement together with fragmentation data. Detection windows in urine are short because the peptide is degraded by proteases and cleared quickly, and concentrations are low. Many jurisdictions treat the compound as a prohibited substance in sport, grouped with peptide hormones and related factors, while it is not an approved therapeutic product. Identity and purity statements therefore rest on certificates of analysis, ideally issued by an independent laboratory.
The compound is most often distributed as a lyophilized powder, appearing white to off-white and forming a loose cake or fluffy solid. It is hygroscopic to some degree, so brief exposure to humid air can add water weight and complicate weighing. The peptide dissolves readily in water and in neutral aqueous buffers, and aqueous solubility is generally described as high, well above the concentrations used in typical assays. Some polar organic solvents are also usable, which matters when a concentrated stock is prepared before dilution into buffer.
Storage recommendations center on keeping the dry powder cold, dry, and dark. A freezer at -20 degrees Celsius or below is conventional, and desiccant is often included to limit moisture uptake. Once dissolved, the peptide is less stable, and solutions are typically kept frozen and thawed only once. Repeated freeze-thaw cycles are a common source of losses because they promote aggregation and adsorption to container surfaces. Working aliquots are therefore prepared in advance, and glass or low-binding plastic is usually preferred over ordinary laboratory plastic.
Identity and purity are assessed with a small set of standard techniques. Reverse-phase high-performance liquid chromatography gives a purity estimate from peak area, usually recorded at 214 or 220 nanometers, where the peptide bond absorbs. Mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidized species. Amino acid analysis or tandem mass spectrometry sequencing can verify the sequence itself. Additional quality attributes include water content, residual trifluoroacetic acid carried over from purification, and endotoxin where the material is intended for biological work.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | Lyophilised cake or powder |
| Solubility class | Freely soluble in water | Aqueous buffers also used |
| Typical storage temperature | About -20 degrees Celsius | Dry, sealed and protected from light |
| Typical analytical method | Reversed-phase HPLC or LC-MS/MS | Used for purity, identity and quantification |
| Common synonyms | Thymosin beta-4 fragment | Also listed under fragment-based descriptions |
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
BrO3− + 5 Br− + 6 H+ → 3 Br2 + 3 H2O There were many failed attempts to obtain perbromates and perbromic acid, leading to some rationalisations as to why they should not exist, until 1968 when the anion was first synthesised from the radioactive beta decay of unstable 83SeO42−. Today, perbromates are produced by the oxidation of alkaline bromate solutions by fluorine gas. Excess bromate and fluoride are precipitated as silver bromate and calcium fluoride, and the perbromic acid solution may be purified. The perbromate ion is fairly inert at room temperature but is thermodynamically extremely oxidising, with extremely strong oxidising agents needed to produce it, such as fluorine or xenon difluoride. The Br–O bond in BrO4− is fairly weak, which corresponds to the general reluctance of the 4p elements arsenic, selenium, and bromine to attain their group oxidation state, as they come after the scandide contraction characterised by the poor shielding afforded by the radial-nodeless 3d orbitals.
In addition, they are commonly prescribed for medical conditions, such as acute respiratory illness, that are usually caused by viral infections. Three mechanisms of resistance are known. Some types of efflux pumps can act to decrease intracellular quinolone concentration. In gram-negative bacteria, plasmid-mediated resistance genes produce proteins that can bind to DNA gyrase, protecting it from the action of quinolones. Finally, mutations at key sites in DNA gyrase or topoisomerase IV can decrease their binding affinity to quinolones, decreasing the drugs' effectiveness.
=== Alcohol use === Lifestyle factors, such as substance use or adiposity, can play a detrimental role in the quality of the semen. One study examining the consequences of alcohol consumption and its effect on semen quality concluded that alcohol intake can lead to a negative effect on semen volume in daily alcohol consumers. However, occasional or moderate use of alcohol was observed to not have an adverse effect on the semen.
Sources: en.wikipedia.org
The Journal of Chromatographic Science (JCS) is a peer reviewed academic journal of chromatography. It is published by Oxford University Press. The Journal focuses on research papers describing practical and preparative applications and analytical methods relevant to a broad range of laboratory work. The editors-in-chief are Huba Kalász and Neil Danielson. According to the Journal Citation Reports, the journal has a 2020 impact factor of 1.618.
Player Luke Davis gave evidence that he was instructed to keep the injections secret from Reid and other coaching staff, although other players disputed that they received such instructions. In May 2012, in a meeting of club administrators including Reid and Dank, Dank was directed to cease giving injections to players; however, evidence given by players indicated that the program was reduced rather than ceased, with many continuing to receive injections until as late as July. Evidence showed that Dank continued to liaise with sports scientists and pharmacists to seek new supplements into August; investigations later described the program as being often experimental in nature. Dank was dismissed from the club in September 2012 because he had made unauthorised expenditures, the exact nature of which was not made public. Essendon's on-field performances during the 2012 season began strongly and finished weakly, a coincidence which was later scrutinised in the context of the program. At the end of May, when the program began to be rewound, the club sat second on the ladder with an 8–1 record. The club then began to lose many players to soft tissue injuries; it won three of its next six games during the middle part of the year to drop to sixth; then lost its last seven games to finish eleventh with an 11–11 record. The CAS acknowledged these observations in its findings, noting that they carried no weight as evidence but describing them as "at least not inconsistent" with the timeline of the program.
various Amanita mushrooms: muscimol Amanita muscaria: ibotenic acid and muscimol Claviceps purpurea and other Clavicipitaceae: ergotamine (not psychoactive itself but used in synthesis of LSD) psilocybin mushrooms: psilocybin and psilocin Psychoactive animals:
== Scientific contributions == Du Vigneaud's career was characterized by an interest in sulfur-containing peptides, proteins, and especially peptide hormones. Even before his Nobel-Prize-winning work on elucidating and synthesizing oxytocin and vasopressin via manipulating the AVP gene, he had established a reputation from his research on insulin, biotin, transmethylation, and penicillin. He also carried out a series of structure-activity relationships for oxytocin and vasopressin, perhaps the first of their type for peptides. That work culminated in the publication of a book entitled A Trail of Research in Sulphur Chemistry and Metabolism and Related Fields.
Sources: en.wikipedia.org
=== Health === On May 18, 2025, Biden's office announced that he had been diagnosed with aggressive prostate cancer with bone metastasis during a routine physical examination. On May 30, Biden confirmed that he had begun treatment. On September 4, Biden's spokesperson confirmed that he had recently undergone Mohs surgery to remove skin cancer lesions from his forehead. The procedure followed a 2023 removal of a basal-cell carcinoma from his chest. On October 11, Biden's spokesperson confirmed that he was undergoing radiation and hormone therapies for his prostate cancer. On October 20, Biden completed a course of radiation therapy at Penn Medicine Radiation Oncology at the University of Pennsylvania. In August 2026, Hunter Biden said the cancer had "spread, metastasized into his bones and further" and was "very painful and it's very debilitating in many respects". In September 2026, Biden announced that the radiation treatment he received for prostate cancer last fall "worked as intended" and that doctors helped in disease control.
=== Third-generation === Third generation antipsychotics are recognized as demonstrating D2 receptor partial agonism as opposed to the D2 and 5HT-2A receptor antagonism of second-generation (atypical) antipsychotics and D2 antagonism of first-generation (typical) antipsychotics.
Thiotepa, as well as its more reactive metabolite, tepa, work as an alkylating agent via its aziridine ring. Due to the basic nature of aziridine and the physiological pH, aziridine is protonated to form the aziridinium ion, resulting in an electrophilic moiety that is highly susceptible to nucleophiles. DNA reacts through the nucleophilic N-7 position of guanine onto the electrophilic aziridine ring, rendering alkylated nucleobases. Thiotepa contains three reactive aziridine rings, allowing a single molecule to alkylate multiple nucleobases. Hence, it is a polyfunctional alkylating agent. This property also gives rise to its ability to cross-link DNA strands. Apart from its mechanism of action, it is suggested that thiotepa can function as a prodrug. Due to its moderate lipophilicity, it first penetrates the cell membrane, followed by hydrolysis to release the more hydrophilic aziridine ring. The aziridine ring can once again alkylate the DNA. The highly reactive metabolite tepa can be considered as an active metabolite and alkylates DNA similar to its parent drug. Ultimately, the alkylation of DNA leads to cell damage and can lead to cell death. Cross-linking blocks the separation of DNA strands, inhibiting replication and the proliferation of cells.
Sources: en.wikipedia.org
Sealed, dry and protected from light at reduced temperature is the usual laboratory convention. Allowing a cold vial to reach room temperature before opening limits condensation. Repeated opening exposes the powder to moisture and should be minimised.
Reported purity reflects the batch tested, the chromatographic method used and whether an independent laboratory performed the work. Values quoted without method detail or a traceable certificate are difficult to compare directly.
Short peptides are rapidly broken down by proteases and appear at low concentrations in urine, so the detection window is narrow. Sensitive extraction combined with tandem mass spectrometry is typically required.
Short transit at ambient temperature is generally tolerated, but long-term storage at room temperature is not recommended. Heat, moisture, and light all accelerate degradation. Cold, dry, dark storage is the conventional choice.